Achillion Pharmaceuticals Inc.





After Hours:




Please Login or Register

Login|Register FREE

Stock Price
Open: 3.70
Prev. Close: 3.68
Low/Hi: 3.55 - 3.83
52-Week: 2.58 - 5.66
Equity: 795,186
90-Day Avg: 2,142,357
Option: 80
90-Day Avg: 497
Todays Stock Vol: 54.7
20-Day (HV): 44.7
52-Week (HV): 53.8
30-Day IV: 64.8 +21.5
IV Pct Rank: 43% Moderate
Div. Yield:
Earnings: 3-May (Est.)
P/E Ratio:
Market Cap: 509.1 M
Short Int Pct: 0.0%
Pct Held By Inst.: 86.4%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

ACHN Stock Posts

Unusual Option Volume

ACHN Achillion Pharmaceuticals4.16+0.15 (+3.7%)

Achillion Pharmaceuticals trades 5,717 contracts. The highest volume is in the 15-Jun-18 5 calls, which is 20.2% above the current price.
Stock Option Volume Spikes 2.5x its Average
ACHN 3.61+0.58 (+19.1%)Achillion Pharmaceuticals
Achillion Pharmaceuticals trades 3,522 contracts. News: Achillion Announces Pricing of Secondary Offering Of Common Stock
Stock Option Volume has Traded 12.9x its Average of 396
ACHN 4.10-0.05 (-1.2%)Achillion Pharmaceuticals
Achillion Pharmaceuticals trades 5,093 contracts. The highest volume is in the 16-Mar-18 7 calls, which is 70.7% above the current price. News: Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
ACHN 4.68+0.67 (+16.7%)Achillion Pharmaceuticals
  • ATM straddle for 15-Sep-17 expiration returned a negative -40.8% from the previous business day
  • The upside wing (25 delta calls) declined -63.6%
  • Downside put (25 delta puts) lost -88.9%
  • The company has the following event: LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on Sep 28, 2017.
  • The option volume for 15-Sep-17 expiration is 2,113
  • News: 3 Biotech Stocks Under the Microscope on Wednesday 8/9/17
Stock Option Volume Spikes 3.7x its Average
ACHN 5.08+1.07 (+26.7%)Achillion Pharmaceuticals
Achillion Pharmaceuticals trades 3,341 contracts. The company has the following event: LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on Sep 28, 2017. News: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
ACHN stock experiences an upside move of +30.4% after seeing unusually high option volume that was heavily weighted toward calls (89.9%). The most active call option was the ACHN 18-Aug-17 5 calls, with volume of 1,606, VWAP 0.22.
Go To Option Chain

Wait, Before You Leave...

Want to Know More About ACHN Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon